Published: 2017-08-02 08:30:00 CEST
Biohit Oyj
Press release

The results of Biohit’s second smoking intervention trial have been published

Biohit Oyj press release 02 August 2017 at 9:30 am. local time (EEST)

The results of the Biohit’s second large-scale smoking intervention trial have been published in the international cancer journal: Anticancer Research.  This randomized placebo-controlled trial (RCT) comprising almost 2000 smokers was completed in May 2017. This study confirmed the previous results obtained in the first RCT, based on a smaller sample size. According to these results,  Acetium® lozenge is an effective means to assist smoking quit, completely free of any side effects.

Chief Medical Director, Professor Kari Syrjänen, Biohit Oyj: ”Acetium lozenge is a safe and effective measure in smoking intervention, because it is a natural product containing xylitol and slow-releasing l-cysteine that binds acetaldehyde from saliva. This product is free from side effects, has no restrictions of use or recommended upper dose limit. A smoker shall take a lozenge together with each smoked cigarette, and the efficacy is based on the principle that after some period of regular use (2-3 months), the taste of the cigarette will change and the sensations of pleasure obtained from smoking will decline, making the decision to quit more easy.”

CEO Semi Korpela, Biohit Oyj: ”This study confirms the results of the previous study, indicating that the likelihood of smoking cessation among regular users of Acetium lozenge was 1.5-fold as compared with the placebo users. Despite all available intervention methods, the decision to stop smoking needs to be made in person.”

ANTICANCER RESEARCH 37: 3639-3648 (2017) doi:10.21873/anticanres.11734

Slow-release L-Cysteine (Acetium®) Lozenge Is an Effective New Method in Smoking Cessation. A randomized, Double-blind, Placebo-controlled Intervention

Press release 22 May 2017 Biohit Acetium® lozenge is a highly effective means to stop smoking – results confirmed in a new large-scale trial


Additional information:
Chief Medical Director, professor Kari Syrjänen, Biohit Oyj or
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.